Agreements reached under this partnership
Co-development and commercialization agreement- 1
Holds the exclusive rights to develop and commercialize lucerastat in Japan, South Korea, Taiwan and certain other Asia-Pacific regions, excluding China
- 2
Cooperate in advancing the global Phase 3 trial
- 3
The Company will participate in the trial comparing the effects on renal function and manage clinical development in Japan
- 4
Idorsia is entitled to receive royalties based on net sales in the applicable territories
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
Global development program targeting regulatory filing as early as 2029
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
The upfront fee has already been reflected in the consolidated earnings forecast for the fiscal year ending December 2026. The progress of lucerastat's development is also expected to contribute to higher business earnings and corporate value for the Group over the medium to long term.
| Item | Details |
|---|---|
| Name of alliance partner | Idorsia Pharmaceuticals Ltd. |
| Alliance partner's business activities | The discovery, development and commercialization of innovative pharmaceuticals. A biopharmaceutical company with experienced specialist personnel across a broad range of areas, from drug discovery research through clinical development and commercialization. |
| Alliance partner's location | Switzerland (near Basel) |
| Type of alliance | Co-development and commercialization agreement |
| Details of the alliance | Holds the exclusive rights to develop and commercialize lucerastat in Japan, South Korea, Taiwan and certain other Asia-Pacific regions, excluding China, Cooperate in advancing the global Phase 3 trial, The Company will participate in the trial comparing the effects on renal function and manage clinical development in Japan, Idorsia is entitled to receive royalties based on net sales in the applicable territories |
| Acquisition price | Upfront fee of 7 million Swiss francs (approximately ¥1,334 million) |
| Numerical targets under the alliance | Global development program targeting regulatory filing as early as 2029 |
| Contract Date | 28 October 2026 |
| Alliance start date | 28 October 2026 (Idorsia commenced the confirmatory Phase 3 trial, FAB-KLEAR, today) |
| Impact on Business Performance | The upfront fee has already been reflected in the consolidated earnings forecast for the fiscal year ending December 2026. The progress of lucerastat's development is also expected to contribute to higher business earnings and corporate value for the Group over the medium to long term. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To in-license lucerastat and expand the late-stage development portfolio in rare diseases in Japan and the Asia-Pacific region. The Company also expects continued development of the drug to contribute to higher business earnings and corporate value over the medium to long term.